Barinthus Biotherapeutics (BRNS)

• Market cap: $25.4M
• 1 day: 1.54%
• 5 days: 2.25%
• 1 month: 2.57%
• 3 months: -11.3%
• 6 months: 7.17%
• Year to date: -15.41%
• 1 year: -47.76%
• 5 years: -95.83%
• 10 years: -95.59%
• Sector: Healthcare
• Industry: Biotechnology

About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Employees: 14